Wainscott, David B.
Eli Lilly (United States)
6 papers on CoChatORCID 0000-0002-8790-1703
Most cited papers
- Verified
Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist
Willard, F. S., Douros, J. D., Gabe, M. B. N., Showalter, A. D., Wainscott, D. B., Suter, T. M., Capozzi, M. E., van der Velden, W. J. C., Stutsman, C., Cardona, G. R., et al. (2020) · JCI Insight
Diabetes Treatment and ManagementReceptor Mechanisms and Signaling
Cited by 541
- Verified
LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: From discovery to clinical proof of concept.
Coskun, T., Urva, S., Roell, W. C., Qu, H., Loghin, C., Moyers, J. S., O’Farrell, L. S., Briere, D. A., Sloop, K. W., Thomas, M. K., et al. (2022) · Cell Metabolism
Diabetes Treatment and ManagementPharmacology and Obesity Treatment
Cited by 316
- Verified
Structural basis for GLP-1 receptor activation by LY3502970, an orally active nonpeptide agonist
Kawai, T., Sun, B., Yoshino, H., Feng, D., Suzuki, Y., Fukazawa, M., Nagao, S., Wainscott, D. B., Showalter, A. D., Droz, B. A., et al. (2020) · Proceedings of the National Academy of Sciences
Receptor Mechanisms and SignalingDiabetes Treatment and Management
Cited by 231
- Verified
The incretin co-agonist tirzepatide requires GIPR for hormone secretion from human islets
El, K., Douros, J. D., Willard, F. S., Novikoff, A., Sargsyan, A., Perez-Tilve, D., Wainscott, D. B., Yang, B., Chen, A., Wothe, D., et al. (2023) · Nature Metabolism
Pancreatic function and diabetesDiabetes Treatment and Management
Cited by 118
- Verified
The pharmacological basis for nonpeptide agonism of the GLP-1 receptor by orforglipron
Sloop, K. W., Cox, A. L., Wainscott, D. B., White, A., Droz, B. A., Stutsman, C., Showalter, A. D., Suter, T. M., Dunbar, J. D., Snider, B. M., et al. (2024) · Science Translational Medicine
Diabetes Treatment and ManagementReceptor Mechanisms and Signaling
Cited by 52
- Verified
679-P: The Novel GIP, GLP-1, and Glucagon Triple Receptor Agonist LY3437943 Exhibits Robust Efficacy in Preclinical Models of Obesity and Diabetes
COSKUN, T., MOYERS, J. S., ROELL, W. C., O’FARRELL, L., REGMI, A., RUAN, X., SHOWALTER, A. D., SLOOP, K., WAINSCOTT, D. B., WILLARD, F. S., et al. (2021) · Diabetes
Diabetes Treatment and ManagementRegulation of Appetite and Obesity
Cited by 10
Go further with a free account
Verify every reference, keep papers in a library, and ask questions across them.
Sign up - it is free